Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Labyrinthin Vaccination for Patients With Lung Adenocarcinomas

NCT07859592 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT07859592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07859592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Labyrinthin Vaccination for Patients With Lung Adenocarcinomas
Lead sponsor
VA Office of Research and Development
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2035
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced, metastatic, recurrent adenocarcinoma and malignant solid neoplasm, type and grade of toxicities, demographic and background characteristics